Patients with difficult-to-treat migraine were randomly assigned 1:1 to either 140 mg erenumab or placebo.
The first-in-class migraine prevention drug will be available to patients within 1 week of the approval.
Researchers assessed the ability of erenumab to decrease the mean number of acute headache days in patients with episodic migraine.
A monthly subcutaneous injection of 70 mg erenumab may represent an effective prophylactic treatment for episodic migraine.
A recent study evaluated the safety and efficacy of erenumab in patients with episodic migraine who had experienced 2 to 4 previous preventive treatment failures, due to lack of efficacy or intolerable side effects.
The monoclonal antibody erenumab has shown favorable results regarding efficacy and safety for the prevention of migraine.
The FDA has accepted for review the Biologics License Application for Aimovig for migraine prophylaxis in patients experiencing more than 4 migraine days per month.
In a phase 3 trial, treatment with erenumab reduced migraine frequency, monthly migraine days, and migraine medication use in patients with episodic migraine.
Clinical Pain Advisor Articles
- Abuse-Deterrent Opioid Formulations: Barriers to Broader Use
- Women Frequently Prescribed High Doses of Opioids After Vaginal Delivery
- Notifications by PDMPs May Not Effectively Reduce Opioid Misuse
- Virtual Reality May Effectively Reduce Sensory, Affective, and Cognitive Pain During Labor
- Medical Cannabis Legalization Associated With Reduced Schedule III Opioid Prescriptions
- Neuropathic Pain Medications
- Higher Buprenorphine Dose May Not Increase Severity of Neonatal Abstinence Syndrome
- Terms Used for Addiction May Be Associated With Explicit, Implicit Bias
- Ketamine Infusions May Be Effective for Refractory Headache
- Physical, Psychosocial Activity May Be Protective Against Development of Chronic Pain in Older Adults
- Prioritizing Rest in Hospital Settings: Poor Sleep Increases Costs, Complications, and Mortality
- Pain Catastrophizing Decreases in Rheumatoid Arthritis After DMARD Initiation
- Addressing Commercial Incentives in the Medical Device Industry
- Cancer Patients Treated With Step III Opioids Often Have Sleep Disturbances
- Low Literacy Self-Management Program for Chronic Pain May Be Effective